



PRESS RELEASE

LANCORA™ (ivabradine) now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure

Laval, Quebec – November 5th, 2018 – Servier Canada Inc. is pleased to announce that following Quebec and Saskatchewan, LANCORA™ is now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure.

LANCORA™ can be prescribed and reimbursed for the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (LVEF) ($\leq 35\%$) in adult patients with New York Heart Association (NYHA) classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats per minute (bpm), to reduce the incidence of cardiovascular mortality and hospitalizations for worsening heart failure, administered in combination with standard chronic heart failure therapies. See individual formulary listings for province specific criteria^{i,ii}.

Over 600 000 Canadians are living with heart failure and 50 000 are diagnosed with the condition every year. Heart failure is a major cause of illness and disability, long and frequent hospital stays and premature death. Heart failure is a complex and incurable condition, resulting in the heart not being able to pump sufficient blood to meet the body's demandsⁱⁱⁱ.

“Increasing access to innovative drugs that not only save lives but also reduce the risk of hospitalization is a major advancement for heart failure patients but also their families and caregivers” said Dr Peter Liu, Chief Scientific Officer and Vice President of Research at the University of Ottawa Heart Institute.

“We are very pleased that patients in Ontario covered by the Ontario Public Drug Program and patients in BC covered by PharmaCare will now have access to the benefits of LANCORA™. LANCORA™ has already been included in the Drug Benefit plans of Quebec and Saskatchewan, and we continue to work with the other provinces so that across Canada, heart failure patients will have equal access to LANCORA™” said Frederic Fasano, Chief Executive Officer of Servier Canada. “Servier is committed to therapeutic progress to serve patient’s needs, all of our activities are centered on this objective.”

About LANCORA™

LANCORA™ (ivabradine) is indicated for the treatment of stable chronic heart failure with reduced left ventricular ejection fraction ($\leq 35\%$) in adult patients with NYHA Classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats per minute, to reduce the incidence of cardiovascular mortality and hospitalisations for worsening heart failure.^{iv}

About Servier Canada

Servier Canada Inc. is an affiliate of the independent French Servier Group. Our mission is to provide the Canadian medical community and its patients with innovative therapeutic solutions. As such, Servier Canada collaborates with various players in the healthcare system including researchers, entrepreneurs and innovators. In addition to these research partners, the Canadian International Center for Therapeutic Research (ICTR) is dedicated to clinical development with more than 50 studies conducted throughout Canada over the last 10 years.

More information is available at www.servier.ca

Media contact:

Nadine DOUCET

Servier Canada

(450) 978-9700 ext. 4225

(514) 601-4881

nadine.doucet@servier.com

-
- i. <https://www.formulary.health.gov.on.ca/formulary/>
 - ii. <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/special-authority#Druglist>
 - iii. The Burden of Heart Failure: 2016 report on the health of Canadians. <https://www.heartandstroke.ca> accessed July 18th, 2018
 - iv. LANCORA Product Monograph, May 2018